Business Context and Reporting Period
This Form 8-K is a current report filed by Tocagen Inc. on December 12, 2018. The filing discloses a material event regarding a public equity offering. Note: The request metadata references "Forte Biosciences, Inc.", but the filing text explicitly identifies the registrant as "Tocagen Inc."
Key Financial Metrics and Transaction Details
- Transaction Type: Underwritten public offering of common stock.
- Shares Offered: 3,000,000 shares of common stock ($0.001 par value).
- Offering Price: $10.00 per share.
- Estimated Net Proceeds: Approximately $27.9 million (after underwriting discounts, commissions, and estimated offering expenses).
- Over-Allotment Option: Underwriters have a 30-day option to purchase up to an additional 450,000 shares.
- Underwriters: Citigroup Global Markets Inc. and Leerink Partners LLC.
- Expected Closing Date: On or about December 17, 2018.
Note: This filing does not provide historical revenue, profit, cash flow, margin, or debt metrics. It focuses solely on the capital raise event.
Material Changes and Outlook
The primary material change is the anticipated increase in cash liquidity resulting from the sale of 3,000,000 shares. The company expects to receive approximately $27.9 million in net proceeds upon closing. The filing includes forward-looking statements regarding the closing of the offering and the receipt of proceeds, which are subject to customary closing conditions and various risks outlined in the company's Form 10-K and 10-Q filings.
Investor Verification Checklist
- Verify the actual closing date of the offering (expected December 17, 2018) and confirm if the over-allotment option was exercised.
- Confirm the final net proceeds received after all expenses, as the $27.9 million figure is an estimate.
- Review the company's Form 10-K for the year ended December 31, 2017, and subsequent 10-Qs for detailed risk factors and historical financial performance.
- Check for any subsequent filings regarding the use of proceeds from this offering.